1) The document discusses balancing access to medicines with innovation, noting that one size may not fit all situations given contingencies in therapeutic markets. 2) It presents perspectives from Adam Smith, Muhammad Yunus, and Hart & Zingales on firms and entrepreneurs having non-profit motives and needing to consider social dimensions. 3) Alternative approaches to patents are discussed, such as priority review vouchers, advance market commitments, and innovation prizes, as well as the roles of venture capital and complementary health infrastructure. 4) The document concludes by framing the issue as responsible firms needing to converge with responsible social planners to find welfare-maximizing solutions, as depicted in a two-by-two matrix